Lacosamid Stada (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. By stabilizing hyper‑excitable neuronal membranes, it reduces the repetitive firing of neurons that can trigger seizure activity, thereby helping to control focal seizures.

The exact dose of lacosamide is individualized by the prescribing clinician based on the patient’s age, renal and hepatic function, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration schedule.

Safety data for lacosamide during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Lacosamid Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with other sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, which may result in a different side‑effect profile and lower risk of certain drug‑drug interactions. Clinical choice depends on individual patient characteristics and therapeutic goals.

Lacosamid Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Lacosamid Stada is administered orally as a tablet. The tablet should be swallowed whole with water, preferably with or without food, as directed by the prescribing physician. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, liver enzyme elevations, hypersensitivity reactions, and the emergence of suicidal thoughts or behaviors. Patients should seek immediate medical attention if any of these events occur.

Lacosamid Stada should be avoided in patients with known severe cardiac conduction disorders (e.g., significant PR‑interval prolongation), hypersensitivity to lacosamide or any excipients, and in individuals where the risk of serious adverse reactions outweighs the therapeutic benefit. A thorough medical assessment is required before initiation.